Stephen Saad Archives

Aspen Pharmacare Asset Disposals: Future Opportunities

Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables

Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen Pharmacare Dispute Ends with R500m Settlement

Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen Targets Mounjaro Expansion in Africa Following Approval

Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen Unlocking Value with New Manufacturing Strategies

Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Aspen secures licensing agreement to enter GLP-1 market

Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here